Bausch + Lomb Corporation
NYSE:BLCOMedical - Instruments & Supplies
+$0.04 today
- Market cap
- $7.49B
- Beta
- 0.57
- P/E (TTM)
- -24.2
- EPS (TTM)
- -$0.62
Volume 0.51M
Average 0.46M
BLCO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Bausch + Lomb CorporationNYSE: BLCO
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables grows, but more slowly than its trailing trend
Q2 FY2026 accounts receivables of $53M (cash outflow) rose 6.0% year over year, behind the +37.3% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Accounts receivables amounted to 2.9% of revenue in FY2025, down 1.8 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +6.0% toward the trailing-twelve-month pace of +37.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (148M) USD
- Year-over-year change
- +34.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (148M) | +34.8% |
| FY2024 | 2024-12-31 | (227M) | -87.6% |
| FY2023 | 2023-12-31 | (121M) | -27.4% |
| FY2022 | 2022-12-31 | (95M) | +11.2% |
| FY2021 | 2021-12-31 | (107M) | — |
Accounts Receivables vs competitors
How BLCO compares with its peers on the latest reported figures
- BLCO's LTM Jun 2026 accounts receivables of $89.24M is the 2nd largest of the 10 companies compared; the peer median is $9.85M.
- Its year-over-year change of +37.3% is the 3rd highest of 8, against a peer median of +1.2%.
- Accounts receivables amounts to 1.7% of revenue for BLCO, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $151.44M | +1.2% | — | 16.9% | |
| LTM Jun 2026 | $89.24M | +37.3% | +15.9% | 1.7% | |
| LTM Jun 2026 | $81.93M | +512.9% | — | 0.5% | |
| LTM Jun 2026 | $67.5M | +15.6% | +30.5% | 2.6% | |
| LTM Jun 2026 | $60.95M | +79.6% | +156.6% | 9.9% | |
| LTM Jun 2026 | $44.38M | -720.6% | -40.6% | 4.4% | |
| LTM Sep 2026 | $9.85M | -15.4% | -43.5% | 0.6% | |
| LTM Sep 2026 | $3.29M | -94.2% | — | 0.7% | |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Sep 2026 | $0 | — | +334.4% | 0.0% | |
| Peer median (excluding BLCO) | $9.85M | +1.2% | +30.5% | 1.7% | |
Competitors are the stored peer set for BLCO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 193M | 15M | (248M) | (305M) | (352M) |
| Depreciation & Amortization | 415M | 379M | 382M | 436M | 421M |
| Deferred Income Tax | 116M | (90M) | (10M) | (10M) | (32M) |
| Stock-Based Compensation | 62M | 62M | 74M | 92M | 149M |
| Change in Working Capital | 28M | (19M) | (287M) | (87M) | 18M |
| Accounts Receivables | (107M) | (95M) | (121M) | (227M) | (148M) |
| Inventory | (15M) | (106M) | (264M) | (147M) | 38M |
| Accounts Payables | 163M | 189M | 245M | 126M | 108M |
| Other Working Capital | (13M) | (7M) | (147M) | 161M | 20M |
| Other Non-Cash Items | 59M | (2M) | 72M | 106M | 79M |
| Operating Cash Flow | 873M | 345M | (17M) | 232M | 283M |
| Capital Expenditures | (193M) | (175M) | (181M) | (291M) | (349M) |
| Acquisitions (Net) | (16M) | 45M | (1.94B) | 0 | 0 |
| Purchases of Investments | (19M) | (62M) | (17M) | (12M) | (11M) |
| Sales of Investments | 14M | 22M | 16M | 14M | 8M |
| Other Investing Activities | 0 | (45M) | 14M | (123M) | (103M) |
| Investing Cash Flow | (214M) | (215M) | (2.11B) | (412M) | (455M) |
| Debt Repayment | 28M | 2.46B | 2.12B | 201M | 249M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | (12M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (740M) | (2.38B) | (37M) | (11M) | (24M) |
| Financing Cash Flow | (712M) | 81M | 2.08B | 178M | 225M |
| Effect of Forex Changes | (8M) | (8M) | 2M | (16M) | 28M |
| Net Change in Cash | (61M) | 203M | (46M) | (18M) | 81M |
| Free Cash Flow | 680M | 170M | (198M) | (59M) | (66M) |
Bausch + Lomb Corporation
NYSE:BLCO
Intrinsic Alpha fair value
Locked
Current Price
$20.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.